Bicara Therapeutics Soars to New Heights: A Pivotal Year of Breakthroughs and Milestones

BCAX

Bicara Therapeutics Soars to New Heights: A Pivotal Year of Breakthroughs and Milestones

In a groundbreaking fourth quarter earnings call, Bicara Therapeutics unveiled an array of remarkable achievements that catapulted the clinical-stage biotech company to unprecedented heights. Under the leadership of CEO Claire Mazumdar, the company has been diligently pioneering bifunctional antibodies for targeted tumor modulation. Their innovative approach combines tumor targeting with

By Julia Horowitz

Latest

PDS Biotechnology Delivers Strong Q4 2025 Results, Advancing Clinical Programs with Promising Treatments for HPV-16 Positive Head and Neck Cancer and Metastatic Castration-Resistant Prostate Cancer

PDS Biotechnology Delivers Strong Q4 2025 Results, Advancing Clinical Programs with Promising Treatments for HPV-16 Positive Head and Neck Cancer and Metastatic Castration-Resistant Prostate Cancer

PDS Biotechnology Corporation has reported a successful fourth quarter of 2025, marked by significant progress across its clinical programs. The company's management team, comprising Dr. Frank Bedu-Addo (Chief Executive Officer), Dr. Kirk Shepherd (Chief Medical Officer), and Lars Boesgaard (Chief Financial Officer), provided an update on the company&

By Mason Lankes